Nov. 9, 2026—Roche has launched the Ventana BAP1 (SP527) Rabbit Monoclonal Primary Antibody. This automated, ready-to-use immunohistochemistry assay is used to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer. It detects nuclear loss of BAP1 expression, a tumor suppressor marker located on chromosome 3p21. Published studies report that loss of nuclear BAP1 on IHC is highly specific for malignancy in mesothelial proliferations. Pathologists use it together with mesothelial lineage markers such as WT1 and calretinin to help confirm a mesothelioma diagnosis.
“Timely differential diagnosis of mesothelioma is critical to help deliver the best outcome for patients,” Matt Sause, CEO of Roche Diagnostics, said in a press release. “Adding BAP1 to our portfolio underscores our commitment to developing innovative solutions that enable health care systems around the world to address diseases with high unmet need, such as mesothelioma.”
The BAP1 assay is registered as an FDA class I IVD and has received IVDR approval as a class C device. It is available worldwide.